BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 21245937)

  • 21. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
    Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
    Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
    Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC
    Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
    Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
    Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
    Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
    Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.
    Rao Gogineni V; Kumar Nalla A; Gupta R; Gorantla B; Gujrati M; Dinh DH; Rao JS
    Int J Oncol; 2010 Apr; 36(4):809-16. PubMed ID: 20198323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.
    Wu F; Catano M; Echeverry R; Torre E; Haile WB; An J; Chen C; Cheng L; Nicholson A; Tong FC; Park J; Yepes M
    J Neurosci; 2014 Oct; 34(43):14219-32. PubMed ID: 25339736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.
    Marconi C; Bianchini F; Mannini A; Mugnai G; Ruggieri S; Calorini L
    Clin Exp Metastasis; 2008; 25(3):225-31. PubMed ID: 18071911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
    Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
    Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.
    Alfano D; Votta G; Schulze A; Downward J; Caputi M; Stoppelli MP; Iaccarino I
    Mol Cell Biol; 2010 Apr; 30(7):1838-51. PubMed ID: 20123981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
    Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
    PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
    Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
    Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
    Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
    J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.